Company intelligence / Profile preview

Verge Therapeutics

South San Francisco, California, United Statesventureradar.com ↗

Ownership: Private
Employees: ~200
Development stage: Preclinical

Overview

Verge Genomics has advanced its lead small molecule program, VRG50635—a PIKfyve inhibitor—into Phase 1 clinical trials for ALS. The company claims rapid progression from target identification to clinic within four years using its proprietary CONVERGE™ AI-driven human genomics platform. Early results focus on safety/tolerability; efficacy data pending as of latest updates.

Therapeutic areas: Neurology
Modalities: Small molecules (e.g., PIKfyve inhibitor)AI-driven drug discovery platform (CONVERGE™)
Industry: Biotech

Partnerships

Eli Lilly & Company — collaboration to discover/develop novel treatments for ALS using the CONVERGE® platform. Lilly has opted into two validated drug targets from this partnership as of November 2024.

Beyond the preview

Go deeper on Verge Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verge Therapeutics.

Explore the full profile